HK1223557A1 - 用於治療局部晚期或轉移性***受體陽性乳腺癌的***受體調節劑 - Google Patents

用於治療局部晚期或轉移性***受體陽性乳腺癌的***受體調節劑

Info

Publication number
HK1223557A1
HK1223557A1 HK16111865.1A HK16111865A HK1223557A1 HK 1223557 A1 HK1223557 A1 HK 1223557A1 HK 16111865 A HK16111865 A HK 16111865A HK 1223557 A1 HK1223557 A1 HK 1223557A1
Authority
HK
Hong Kong
Prior art keywords
estrogen receptor
treatment
breast cancer
locally advanced
positive breast
Prior art date
Application number
HK16111865.1A
Other languages
English (en)
Inventor
Maneval Edna Chow
Bao Tran H Truong
Isan Chen
Jeffrey H Hager
Debasish F Roychowdhury
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1223557A1 publication Critical patent/HK1223557A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16111865.1A 2013-12-06 2016-10-14 用於治療局部晚期或轉移性***受體陽性乳腺癌的***受體調節劑 HK1223557A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913167P 2013-12-06 2013-12-06
US201461981672P 2014-04-18 2014-04-18
PCT/IB2014/002679 WO2015082990A1 (en) 2013-12-06 2014-12-05 Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer

Publications (1)

Publication Number Publication Date
HK1223557A1 true HK1223557A1 (zh) 2017-08-04

Family

ID=52347358

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111865.1A HK1223557A1 (zh) 2013-12-06 2016-10-14 用於治療局部晚期或轉移性***受體陽性乳腺癌的***受體調節劑

Country Status (12)

Country Link
US (2) US9675586B2 (zh)
EP (1) EP3089747A1 (zh)
JP (1) JP2016540767A (zh)
KR (1) KR20160085915A (zh)
CN (1) CN105916501A (zh)
AU (1) AU2014358850A1 (zh)
CA (1) CA2932106A1 (zh)
HK (1) HK1223557A1 (zh)
IL (1) IL245758A0 (zh)
MX (1) MX2016007282A (zh)
SG (1) SG11201604501TA (zh)
WO (1) WO2015082990A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
MX2015017655A (es) 2013-06-19 2016-04-15 Seragon Pharmaceuticals Inc Modulador de receptores de estrogeno y uso del mismo.
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
US20180173846A1 (en) * 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
AR101487A1 (es) 2014-08-11 2016-12-21 Hoffmann La Roche Formas cristalinas de un modulador de receptor de estrógeno
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
US9980947B2 (en) 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
US9975856B2 (en) 2015-10-07 2018-05-22 Genentech, Inc. Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
CN107428758B (zh) 2015-11-12 2020-08-04 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
MX2018011419A (es) 2016-04-01 2019-06-06 Zeno Royalties & Milestones Llc Moduladores de receptores estrogénicos.
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
AU2018287988A1 (en) * 2017-06-20 2019-10-10 Breast Cancer Now Methods and medical uses
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
EP3498273A1 (en) * 2017-12-14 2019-06-19 Universität Wien Pharmaceutical composition for modulating the response of a gaba-a receptor
WO2019211322A1 (en) * 2018-05-02 2019-11-07 Mithra Pharmaceuticals S.A. Treatment of advanced estrogen receptor positive breast cancer
UA128114C2 (uk) 2018-06-21 2024-04-10 Ф. Хоффманн-Ля Рош Аг Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування
ES2923412T3 (es) 2018-09-07 2022-09-27 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
SG11202111979SA (en) * 2019-05-09 2021-11-29 Sanofi Sa 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
JP2022534037A (ja) 2019-05-24 2022-07-27 浙江海正薬業股▲ふん▼有限公司 アクリル酸系誘導体の結晶形およびその調製方法及び用途
EP3993787A4 (en) 2019-08-06 2023-07-12 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
NZ630124A (en) 2012-03-20 2016-01-29 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.

Also Published As

Publication number Publication date
EP3089747A1 (en) 2016-11-09
US10034860B2 (en) 2018-07-31
WO2015082990A1 (en) 2015-06-11
CN105916501A (zh) 2016-08-31
JP2016540767A (ja) 2016-12-28
AU2014358850A8 (en) 2016-08-04
WO2015082990A8 (en) 2016-07-21
US20170239219A1 (en) 2017-08-24
IL245758A0 (en) 2016-07-31
US20150157606A1 (en) 2015-06-11
CA2932106A1 (en) 2015-06-11
US9675586B2 (en) 2017-06-13
SG11201604501TA (en) 2016-07-28
KR20160085915A (ko) 2016-07-18
MX2016007282A (es) 2016-09-07
AU2014358850A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
HK1223557A1 (zh) 用於治療局部晚期或轉移性***受體陽性乳腺癌的***受體調節劑
HUS2400002I1 (hu) Mellrák kezelése szelektív ösztrogénreceptor-módosítók alkalmazásával
IL237558A0 (en) Methods for treating locally advanced breast cancer
IL245196B (en) Antibodies against cd38 for the treatment of human cancers
IL245731A0 (en) Combined treatment for cancer
PT3033086T (pt) Terapia de combinação para o tratamento de cancro
EP2968343A4 (en) POLY THERAPY FOR TREATING CANCER
HK1222869A1 (zh) 用於治療癌症的針對 的偶聯抗體
HK1219737A1 (zh) 用於治療癌症的新化合物
HK1222548A1 (zh) 治療惡性腫瘤的藥物組合
HK1213909A1 (zh) 通過調節 治療乳腺癌
IL281541A (en) Specific anti-cd38 antibodies for treating human cancers
HK1223547A1 (zh) 癌症治療方法
IL245551A0 (en) Anti-matriptase antibodies for cancer treatment
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
EP3077812A4 (en) Methods for the prognosis of breast cancer
GB201321531D0 (en) Treatment for cancers
AP2015008905A0 (en) Novel compounds for the treatment of cancer
GB201300546D0 (en) Cancer Treatment